CV Safety Requirements For Motility Drugs Could Take Indication-Centric Approach
This article was originally published in The Pink Sheet Daily
Executive Summary
At a Nov. 17 meeting on 5-HT4 receptor agonists, FDA will ask advisory committee members whether an increased cardiovascular risk would be acceptable depending upon the context of use and whether sponsors need to conduct a dedicated CV study either before or after approval.